Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Interview: GW Pharma Gears Up For Pivotal 2018

Executive Summary

The UK group has raised nearly $320m this week which will be used to build commercial organizations in the US and Europe ahead of potential approvals for its cannabinoid epilepsy therapy Epidiolex.

Advertisement

Related Content

The Year's Clinical Trials In Review: Big Hits In 2017
Finance Watch: The Year's Biggest IPO And A Post-ASH Offering Splash
Cannabis Derivative Sativex 'Shows Promise In US Patients' Despite Further Phase III Failure

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100042

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel